Silver Book Fact

The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.

Romley, John A., Yuri Sanchez, John R. Penrod, Dana P. Goldman. Survery Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs. Health Affairs. 2012; 31(4): 683-690

Reference

Title
Survery Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2012
Authors
Romley, John A., Yuri Sanchez, John R. Penrod, Dana P. Goldman
Volume & Issue
Volume 31, Issue 4
Pages
683-690

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The 5-year survival rate for all cancers diagnosed from 1996-2003 is 66%, up from 50% in 1975-1977. This improvement reflects progress in early diagnosis and improvements in treatment.  
  • According to the Pharmaceutical Research and Manufacturers of America, researchers are currently working on 646 medicines for cancer. All are either in clinical trials or under FDA review. …  
  • For women age 40 or older, timely mammograms could reduce breast cancer mortality by about 16%–compared to those who are not screened.  
  • 750 cancer-fighting medicines are currently in development.  
  • Death rates from breast cancer have steadily decreased in women since 1990. This decrease represents progress in both early detection and improved treatment.